Elixinol Wellness completed the sale of its minority stake in Pet Releaf, receiving $2.3 million.

The move aligns with its strategy to streamline investments and focus on core business. With FY24 first-quarter revenue at $3M, the company is optimising its portfolio for growth.

David Fenlon, non-executive chair, noted the divestiture as a step towards break-even.